Items tagged with Scientific research
Europe and Africa double research efforts to tackle AIDS, Ebola and other infectious diseases (post)
Cape Town, South Africa, 02 December 2014
Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant (post)
Clinical trial in HIV-infected adults showed good safety and immunogenicity
Scientists' unique system of oral vaccine delivery to address global health threats (post)
Developments in oral immunization delivery viewed as potential weapon to combat global health threats such as tuberculosis, AIDS and diarrheas
A biosensor to peer into insides of HIV-infected cell (post)
A new biosensor can measure what is going on within HIV-infected cells in real-time and also provide insight on the interactions between the AIDS virus and the tuberculosis causing bacteria within the cells.
Developing new tuberculosis drugs from marine natural products: Joint research program between OPBIO and TB Alliance announced (post)
OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance). The research program involves the discovery of candidate compounds for tuberculosis (TB) drugs in partnership with TB Alliance.
New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency (post)
While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. New research conducted at the Center for Tuberculosis Research at the Johns Hopkins University School of Medicine shows that lower doses of the toxic drug bedaquiline — given together with verapamil, a medication that’s used to treat various heart conditions — can lead to the same antibacterial effects as higher toxic doses of bedaquiline. The combination of the two drugs could potentially shorten treatment time, reduce the side effects of bedaquiline and improve patient outcomes for those suffering from TB.
NovoBiotic reports the discovery of teixobactin, a new antibiotic without detectable resistance (post)
No resistant mutants of either S. aureus or Mycobacterium tuberculosis could be generated
Stop subsidizing Big Pharma (post)
WASHINGTON — ROBERT J. BEALL, the president and chief executive of the Cystic Fibrosis Foundation, called his recent decision to sell the royalty rights to his organization’s research a “game changer.” Indeed: Deals like this, in which an investment company paid the foundation $3.3 billion for its future royalties from several cystic fibrosis drugs it helped finance, could revolutionize the way medical research is funded. Rather than the staid model of government-funded institutions handing out grants to academic research facilities, a new breed of “venture philanthropies” like the Cystic Fibrosis Foundation could corral private investment into developing lifesaving drugs quickly and cheaply.
Scientists find drug candidate for TB, malaria (post)
Indian scientists have created a common drug candidate capable of tackling tuberculosis (TB) and malaria–the nation’s two most common health problems–though it will take several years before the breakthrough in the laboratory is translated into a medicine.
U.S. senators re-introduce a bill to speed approval of antibiotics (post)
In the latest bid to combat antibiotic resistance, two U.S. senators have re-introduced legislation to create a so-called regulatory pathway to hasten approval of new treatments.
Page 6 of 74 · Total posts: 0
←First 5 6 7 Last→